Comparative effectiveness of trimethoprim-sulfamethoxazole dosing strategies for Pneumocystis jirovecii pneumonia: a target trial emulation.
OBJECTIVES Trimethoprim-sulfamethoxazole (TMP-SMX) is considered first-line therapy for Pneumocystis pneumonia (PCP); however, dosing recommendations have remained largely unchanged since the 1970s. Current dosing may increase adverse effects without clear beneficial outcomes. This study evaluated the comparative effec...